Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznań, Poland.
Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznań, Poland.
Biomed Pharmacother. 2017 Aug;92:836-842. doi: 10.1016/j.biopha.2017.05.146. Epub 2017 Jun 7.
Tumors of the female reproductive tract are an important target for the development of diagnostic, prognostic and therapeutic strategies. Recent research has turned to proteomics based on mass spectrometry techniques, to achieve more effective diagnostic results. Mass spectrometry (MS) enables identification and quantification of multiple molecules simultaneously in a single experiment according to mass to charge ratio (m/z). Several proteomic strategies may be applied to establish the function of a particular protein/peptide or to identify a novel disease and specific biomarkers related to it. Therefore, MS could facilitate treatment in patients with tumors by helping researchers discover new biomarkers and narrowly targeted drugs. This review presents a comprehensive discussion of mass spectrometry as a tool for biomarkers searching that may lead to the discovery of easily available diagnostic tests in gynecological oncology with emphasis on clinical proteomics over the past decade. The article provides an insight into different MS based proteomic approaches.
女性生殖系统肿瘤是开发诊断、预后和治疗策略的重要目标。最近的研究转向了基于质谱技术的蛋白质组学，以获得更有效的诊断结果。质谱 (MS) 能够根据质荷比 (m/z) 在单次实验中同时鉴定和定量多种分子。可以应用几种蛋白质组学策略来确定特定蛋白质/肽的功能，或鉴定与特定疾病相关的新型标志物。因此，MS 通过帮助研究人员发现新的生物标志物和靶向药物，可促进肿瘤患者的治疗。本文全面讨论了 MS 作为一种生物标志物搜索工具，它可能会发现妇科肿瘤学中更容易获得的诊断测试，重点介绍过去十年的临床蛋白质组学。文章深入探讨了基于 MS 的不同蛋白质组学方法。
